Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Isoquercetin as an Adjunct Therapy in Patients With Kidney Cancer Receiving First-line Sunitinib: a Phase I/II Trial

NCT02446795 is registered in ClinicalTrials.gov with Consorzio Oncotech as lead sponsor.

NCT NCT02446795
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02446795 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Isoquercetin as an Adjunct Therapy in Patients With Kidney Cancer Receiving First-line Sunitinib: a Phase I/II Trial
Lead sponsor
Consorzio Oncotech
Phase
Phase 1/2
Overall status
Unknown status
Start date
November 30, 2016
Completion date
December 31, 2017
Enrollment
104 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

kidney cancer, renal cell carcinoma